{"id":"W2558149620","doi":"10.1182/blood.v116.21.4758.4758","title":"Dose Adjustment and Treatment Interruptions Associated with Second-Line Nilotinib or Dasatinib In Real-World Treatment of Chronic Myeloid Leukemia","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Group for Research in Decision Analysis","funders":"","keywords":"Nilotinib; Dasatinib; Medicine; Internal medicine; Myeloid leukemia; Imatinib; Tyrosine-kinase inhibitor; Adverse effect; Imatinib mesylate; Oncology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00443346,0.0001870217,0.0006492395,0.001312838,0.000411956,0.001127383,0.0006594461,0.0006702467,0.002112379],"category_scores_gemma":[0.02278417,0.0002402666,0.0008083185,0.003441888,0.0003859133,0.0007000666,0.0007338459,0.001037751,0.0001979095],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001880393,"about_ca_system_score_gemma":0.001341605,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003366512,"about_ca_topic_score_gemma":0.003786545,"domain_scores_codex":[0.9906206,0.00304586,0.00213265,0.001557064,0.002114324,0.0005295195],"domain_scores_gemma":[0.9476525,0.01160145,0.037165,0.0009231389,0.001535159,0.001122903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.00211216,0.0002002638,0.9871024,0.0001780876,0.0003307689,0.0002497982,0.0002206064,0.0002858629,0.0001767656,0.00008814907,0.0005273377,0.008527783],"study_design_scores_gemma":[0.0002603279,0.0008167975,0.9931211,0.00008898178,0.0002698887,0.001211463,0.0004110956,0.001889514,0.0002542865,0.00009920058,0.001556793,0.00002064681],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9957825,0.001512102,0.0001859845,0.0002396598,0.000007506498,0.00006286091,0.001444847,0.000009080368,0.0007555865],"genre_scores_gemma":[0.9984848,0.0002829678,0.000153736,0.00008809612,0.00001213769,0.00003717,0.0008909833,0.000003000687,0.0000471042],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00443346,"threshold_uncertainty_score":0.02344662,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03358066553018203,"score_gpt":0.3035751965710189,"score_spread":0.2699945310408369,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}